CBUS
Price
$2.47
Change
-$0.16 (-6.08%)
Updated
Jan 24, 11:16 AM (EDT)
Capitalization
69.58M
VRDN
Price
$18.76
Change
+$0.41 (+2.23%)
Updated
Jan 23 closing price
Capitalization
1.49B
33 days until earnings call
Ad is loading...

CBUS vs VRDN

Header iconCBUS vs VRDN Comparison
Open Charts CBUS vs VRDNBanner chart's image
Cibus
Price$2.47
Change-$0.16 (-6.08%)
Volume$100
Capitalization69.58M
Viridian Therapeutics
Price$18.76
Change+$0.41 (+2.23%)
Volume$968.6K
Capitalization1.49B
CBUS vs VRDN Comparison Chart
Loading...
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CBUS vs. VRDN commentary
Jan 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBUS is a StrongBuy and VRDN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 24, 2025
Stock price -- (CBUS: $2.63 vs. VRDN: $18.76)
Brand notoriety: CBUS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CBUS: 137% vs. VRDN: 65%
Market capitalization -- CBUS: $69.58M vs. VRDN: $1.49B
CBUS [@Biotechnology] is valued at $69.58M. VRDN’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $360.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CBUS’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • CBUS’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, CBUS is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CBUS’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 1 bullish TA indicator(s).

  • CBUS’s TA Score: 4 bullish, 3 bearish.
  • VRDN’s TA Score: 1 bullish, 3 bearish.
According to our system of comparison, CBUS is a better buy in the short-term than VRDN.

Price Growth

CBUS (@Biotechnology) experienced а +6.48% price change this week, while VRDN (@Biotechnology) price change was +9.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.00%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was -0.35%.

Reported Earning Dates

CBUS is expected to report earnings on Aug 09, 2023.

VRDN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+5.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.49B) has a higher market cap than CBUS($69.6M). VRDN YTD gains are higher at: -2.139 vs. CBUS (-5.396). VRDN has higher annual earnings (EBITDA): -253.41M vs. CBUS (-492.98M). VRDN has more cash in the bank: 753M vs. CBUS (28.8M). VRDN has less debt than CBUS: VRDN (21.1M) vs CBUS (36.7M). CBUS has higher revenues than VRDN: CBUS (4.15M) vs VRDN (302K).
CBUSVRDNCBUS / VRDN
Capitalization69.6M1.49B5%
EBITDA-492.98M-253.41M195%
Gain YTD-5.396-2.139252%
P/E RatioN/AN/A-
Revenue4.15M302K1,375%
Total Cash28.8M753M4%
Total Debt36.7M21.1M174%
FUNDAMENTALS RATINGS
CBUS vs VRDN: Fundamental Ratings
CBUS
VRDN
OUTLOOK RATING
1..100
412
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9461
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CBUS's Valuation (17) in the null industry is significantly better than the same rating for VRDN (92) in the Biotechnology industry. This means that CBUS’s stock grew significantly faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for CBUS (100) in the null industry. This means that VRDN’s stock grew somewhat faster than CBUS’s over the last 12 months.

VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as CBUS (99) in the null industry. This means that VRDN’s stock grew similarly to CBUS’s over the last 12 months.

VRDN's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for CBUS (94) in the null industry. This means that VRDN’s stock grew somewhat faster than CBUS’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CBUS (100) in the null industry. This means that VRDN’s stock grew similarly to CBUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CBUSVRDN
RSI
ODDS (%)
Bullish Trend 17 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 17 days ago
88%
Bearish Trend 17 days ago
85%
Momentum
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 17 days ago
85%
MACD
ODDS (%)
Bullish Trend 17 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 17 days ago
89%
Bearish Trend 17 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 17 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
84%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 17 days ago
89%
N/A
View a ticker or compare two or three
Ad is loading...
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IARRX16.960.12
+0.71%
Invesco Real Estate R
NAPIX59.990.23
+0.38%
Voya Multi-Manager International Sm Cp I
PEGEX22.840.08
+0.35%
PGIM Jennison Mid-Cap Growth R2
FNCMX254.230.56
+0.22%
Fidelity Nasdaq Composite Index
RECIX12.09N/A
N/A
RBC Emerging Markets Ex-China Equity I

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with ALLO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+2.23%
ALLO - VRDN
51%
Loosely correlated
-2.08%
FATE - VRDN
49%
Loosely correlated
N/A
AURA - VRDN
47%
Loosely correlated
+2.14%
ABCL - VRDN
45%
Loosely correlated
-0.28%
CRBU - VRDN
45%
Loosely correlated
N/A
More